Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

325 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor-β tyrosine kinase inhibitor, in patients with recurrent glioblastoma.
Batchelor TT, Gerstner ER, Ye X, Desideri S, Duda DG, Peereboom D, Lesser GJ, Chowdhary S, Wen PY, Grossman S, Supko JG. Batchelor TT, et al. Among authors: chowdhary s. Neuro Oncol. 2017 Apr 1;19(4):567-575. doi: 10.1093/neuonc/now185. Neuro Oncol. 2017. PMID: 27663390 Free PMC article. Clinical Trial.
Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma.
Reardon DA, Nabors LB, Mason WP, Perry JR, Shapiro W, Kavan P, Mathieu D, Phuphanich S, Cseh A, Fu Y, Cong J, Wind S, Eisenstat DD; BI 1200 36 Trial Group and the Canadian Brain Tumour Consortium. Reardon DA, et al. Neuro Oncol. 2015 Mar;17(3):430-9. doi: 10.1093/neuonc/nou160. Epub 2014 Aug 19. Neuro Oncol. 2015. PMID: 25140039 Free PMC article. Clinical Trial.
Phase I/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed/refractory glioblastoma (phase II).
Hainsworth JD, Becker KP, Mekhail T, Chowdhary SA, Eakle JF, Wright D, Langdon RM, Yost KJ, Padula GDA, West-Osterfield K, Scarberry M, Shaifer CA, Shastry M, Burris HA 3rd, Shih K. Hainsworth JD, et al. J Neurooncol. 2019 Sep;144(2):303-311. doi: 10.1007/s11060-019-03227-7. Epub 2019 Aug 7. J Neurooncol. 2019. PMID: 31392595 Clinical Trial.
Bevacizumab for the treatment of glioblastoma.
Chowdhary S, Chamberlain M. Chowdhary S, et al. Expert Rev Neurother. 2013 Aug;13(8):937-49. doi: 10.1586/14737175.2013.827414. Epub 2013 Aug 16. Expert Rev Neurother. 2013. PMID: 23952194 Review.
Modified RANO, Immunotherapy RANO, and Standard RANO Response to Convection-Enhanced Delivery of IL4R-Targeted Immunotoxin MDNA55 in Recurrent Glioblastoma.
Ellingson BM, Sampson J, Achrol AS, Aghi MK, Bankiewicz K, Wang C, Bexon M, Brem S, Brenner A, Chowdhary S, Floyd JR, Han S, Kesari S, Randazzo D, Vogelbaum MA, Vrionis F, Zabek M, Butowski N, Coello M, Merchant N, Merchant F. Ellingson BM, et al. Among authors: chowdhary s. Clin Cancer Res. 2021 Jul 15;27(14):3916-3925. doi: 10.1158/1078-0432.CCR-21-0446. Epub 2021 Apr 16. Clin Cancer Res. 2021. PMID: 33863808 Free PMC article. Clinical Trial.
Handedness and the risk of glioma.
Miller B, Peeri NC, Nabors LB, Creed JH, Thompson ZJ, Rozmeski CM, LaRocca RV, Chowdhary S, Olson JJ, Thompson RC, Egan KM. Miller B, et al. Among authors: chowdhary s. J Neurooncol. 2018 May;137(3):639-644. doi: 10.1007/s11060-018-2759-y. Epub 2018 Jan 13. J Neurooncol. 2018. PMID: 29332185 Free PMC article.
325 results